Silver Andrew Jacob
Silver Andrew Jacob, CFO, reported a transaction classified as grant at CRISPR Therapeutics AG involving 25000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 25000.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Oct 19, 2026
- Filing date
- Oct 21, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
CRSP price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- grant Code A
- Identifier
- 0001193125-26-428010 Restricted Stock Units
- Transaction date
- Oct 19, 2026 Filed Oct 21, 2026, 09:41 PM · 2d delay
- Shares
- 25,000 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 25,000 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-6 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 2
Filing reported within two business days of the transaction. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Chief Financial Officer
- F1
Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- F2
This restricted stock unit award was granted on October 19, 2026 with respect to 25,000 Common Shares, with 100% of the shares vesting on October 19, 2028.
0 other transactions
0 recent txs